Santiago Gardella

Learn More
The aim of the present randomized trial was to compare high-dose therapy (HDT) with continued conventional chemo-therapy in patients with multiple myeloma (MM) who responded to the initial treatment .sponding patients were randomly assigned to receive 8 additional cycles of VBMCP/VBAD, intensification with mel-phalan 200 mg/m 2 , or melphalan 140 mg/m 2(More)
We show that interleukin-18 is constitutively produced by dendritic cells; synthesis and secretion are poorly affected by maturative stimuli. Challenge of dendritic cells with autologous anti-tetanus toxoid T lymphocytes results in a secretory switch, with induction of secretion of biologically active interleukin-18 and decrease of its intracellular(More)
BACKGROUND Melphalan and prednisone (MP) has been the standard treatment for multiple myeloma (MM) for the last 30 years. Combination chemotherapy at conventional doses has not shown a significant prolongation of survival when compared to MP. There are few data comparing conventional chemotherapy at standard doses with conventional treatment at higher(More)
REDG-136-O from the Fondo de Investigaciones Sanitarias de la Seguridad Social. The authors want to thank Dr. Jordi Esteve for his help in the statistical analysis and Mª José Sánchez-Melero for her outstanding secretarial support. 2 JB and JS made the initial conception/design of the trial, analyzed and interpreted the data, wrote the first draft, modified(More)
BACKGROUND Purine analogs have demonstrated significant activity in patients with follicular lymphoma. The aim of this study was to analyze the efficacy and toxicity of a fludarabine combination as first-line treatment in patients with advanced-stage disease. DESIGN AND METHODS This is a phase II trial including 120 patients (< or =65 years) treated with(More)
BACKGROUND Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease. DESIGN AND METHODS In the Spanish Myeloma Group 2000 trial, 80(More)
  • 1